GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESAIY) » Definitions » Cyclically Adjusted PS Ratio

ESAIY (Eisai Co) Cyclically Adjusted PS Ratio : 0.61 (As of Jun. 01, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Eisai Co Cyclically Adjusted PS Ratio?

As of today (2025-06-01), Eisai Co's current share price is $7.14. Eisai Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $11.80. Eisai Co's Cyclically Adjusted PS Ratio for today is 0.61.

The historical rank and industry rank for Eisai Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

ESAIY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.5   Med: 0.87   Max: 1.54
Current: 0.59

During the past years, Eisai Co's highest Cyclically Adjusted PS Ratio was 1.54. The lowest was 0.50. And the median was 0.87.

ESAIY's Cyclically Adjusted PS Ratio is ranked better than
82.79% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs ESAIY: 0.59

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eisai Co's adjusted revenue per share data for the three months ended in Mar. 2025 was $1.113. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $11.80 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eisai Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eisai Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Cyclically Adjusted PS Ratio Chart

Eisai Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.95 0.75 0.98 0.84 0.59

Eisai Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.90 0.74 0.60 0.59

Competitive Comparison of Eisai Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eisai Co's Cyclically Adjusted PS Ratio falls into.


;
;

Eisai Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eisai Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=7.14/11.80
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eisai Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Eisai Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.113/111.1000*111.1000
=1.113

Current CPI (Mar. 2025) = 111.1000.

Eisai Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 3.930 98.400 4.437
201509 3.960 98.500 4.467
201512 4.332 98.100 4.906
201603 3.753 97.900 4.259
201606 4.543 98.100 5.145
201609 4.560 98.000 5.170
201612 4.193 98.400 4.734
201703 4.015 98.100 4.547
201706 4.465 98.500 5.036
201709 4.513 98.800 5.075
201712 4.783 99.400 5.346
201803 5.280 99.200 5.913
201806 4.859 99.200 5.442
201809 4.881 99.900 5.428
201812 4.885 99.700 5.444
201903 5.505 99.700 6.134
201906 4.971 99.800 5.534
201909 4.713 100.100 5.231
201912 5.973 100.500 6.603
202003 6.782 100.300 7.512
202006 5.368 99.900 5.970
202009 5.003 99.900 5.564
202012 6.092 99.300 6.816
202103 4.736 99.900 5.267
202106 1.575 99.500 1.759
202109 5.175 100.100 5.744
202112 1.555 100.100 1.726
202203 1.404 101.100 1.543
202206 1.199 101.800 1.309
202209 1.061 103.100 1.143
202212 1.212 104.100 1.293
202303 1.293 104.400 1.376
202306 1.215 105.200 1.283
202309 1.041 106.200 1.089
202312 1.076 106.800 1.119
202403 1.108 107.200 1.148
202406 1.045 108.200 1.073
202409 1.203 108.900 1.227
202412 1.237 110.700 1.241
202503 1.113 111.100 1.113

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eisai Co  (OTCPK:ESAIY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eisai Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eisai Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.